NEWS
Strong validation of Evaxion’s AI-Immunology™ platform in multiple clinical trials
Evaxion Biotech A/S (NASDAQ: EVAX) has reported strong validation of its AI-Immunology™ platform in multiple clinical trials. The company, specializing in AI-powered vaccine development, has gathered evidence from three separate clinical trials demonstrating the platform's ability to select clinically relevant vaccine targets.
Key findings include:
Statistically significant correlation between AI-Immunology™ prediction scores and immunological responses in patients
Strongest outcomes generated by top-ranked AI-Immunology™ vaccine targets
In one trial, a statistically significant correlation between AI-Immunology™ prediction scores and Progression Free Survival (PFS)
Key findings include:
Statistically significant correlation between AI-Immunology™ prediction scores and immunological responses in patients
Strongest outcomes generated by top-ranked AI-Immunology™ vaccine targets
In one trial, a statistically significant correlation between AI-Immunology™ prediction scores and Progression Free Survival (PFS)
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
2595Followers
107Following
28KVisitors
Follow